Literature DB >> 3806374

Implementation and evaluation of control strategies for individualizing dosage regimens, with application to the aminoglycoside antibiotics.

D Katz, D Z D'Argenio.   

Abstract

Three strategies are implemented for controlling serum concentrations by determining individualized dosage regimens. The methods incorporate, respectively, nonlinear least squares parameter estimation, Bayesian maximum a posteriori probability estimation, and a stochastic control procedure that minimizes the expected value of an appropriate therapeutic cost. The performance of the three dose regimen calculation strategies was evaluated using Monte Carlo simulations of a typical therapeutic protocol for tobramycin.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3806374     DOI： 10.1007/bf01059659

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN： 0090-466X


  5 in total

1.  Forecasting individual pharmacokinetics.

Authors:  L B Sheiner; S Beal; B Rosenberg; V V Marathe
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

2.  Modelling of individual pharmacokinetics for computer-aided drug dosage.

Authors:  L B Sheiner; B Rosenberg; K L Melmon
Journal:  Comput Biomed Res       Date:  1972-10

3.  A priori lithium dosage regimen using population characteristics of pharmacokinetic parameters.

Authors:  J Gaillot; J L Steimer; A J Mallet; J J Thebault; A Bieder
Journal:  J Pharmacokinet Biopharm       Date:  1979-12

4.  Methods for evaluating optimal dosage regimens and their application to theophylline.

Authors:  O Richter; D Reinhardt
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1982-12

5.  Kinetic model for gentamicin dosing with the use of individual patient parameters.

Authors:  R J Sawchuk; D E Zaske; R J Cipolle; W A Wargin; R G Strate
Journal:  Clin Pharmacol Ther       Date:  1977-03       Impact factor: 6.875
  5 in total
  10 in total

1.  Use of a pharmacokinetic/pharmacodynamic model to design an optimal dose input profile.

Authors:  K Park; D Verotta; S K Gupta; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1998-08

2.  Bayesian individualization via sampling-based methods.

Authors:  J Wakefield
Journal:  J Pharmacokinet Biopharm       Date:  1996-02

3.  Nonparametric maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine.

Authors:  A Mallet; F Mentré; J L Steimer; F Lokiec
Journal:  J Pharmacokinet Biopharm       Date:  1988-06

4.  A Nonparametric Method to Optimize Initial Drug Dosing and Attainment of a Target Exposure Interval: Concepts and Application to Busulfan in Pediatrics.

Authors:  Michaël Philippe; Michael Neely; Yves Bertrand; Nathalie Bleyzac; Sylvain Goutelle
Journal:  Clin Pharmacokinet       Date:  2017-04       Impact factor: 6.447

5.  Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs.

Authors:  Tawanda Gumbo; Jan-Willem C Alffenaar
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

Review 6.  Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods?

Authors:  M M Tod; C Padoin; O Petitjean
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

7.  Targeting the systemic exposure of teniposide in the population and the individual using a stochastic therapeutic objective.

Authors:  D Z D'Argenio; J H Rodman
Journal:  J Pharmacokinet Biopharm       Date:  1993-04

8.  Implementation and evaluation of a stochastic control strategy for individualizing teicoplanin dosage regimen.

Authors:  M Tod; P Alet; O Lortholary; O Petitjean
Journal:  J Pharmacokinet Biopharm       Date:  1997-12

9.  Aminoglycoside forecasting in neutropenic patients with cancer.

Authors:  J L Kosirog; R M Rospond; C Destache; P Hall
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

10.  Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.

Authors:  Shashikant Srivastava; Devyani Deshpande; Jotam Pasipanodya; Eric Nuermberger; Soumya Swaminathan; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2016-11-01       Impact factor: 9.079
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.